The lack of prospective registration, independent
Research gap analysis derived from 3 medicine papers in our local library.
The gap
The lack of prospective registration, independent screening and extraction, and validated risk-of-bias assessment. The absence of a reproducible chain linking authenticated and chemically defined materials to dose, exposure, pharmacological
Evidence profile
Sourced from the limitations section and stated challenges and conclusions of the source papers, classified as general, all from Frontiers in Pharmacology.
Research trend
Established — well-defined area with open sub-problems.
Supporting evidence — 3 representative gaps
- Editorial: Nutraceuticals modulation for oxidative stress in disease and health: volume II (2026) · Frontiers in Pharmacology · doi
the gap in which promising preclinical results fail to translate into human efficacy due to poor bioavailability, formulation instability and toxicity concerns, - the study by Tian et al. speculated that the association is attributed to reverse causation, - the untested hypothesis requires further validation, - the transition from the laboratory to population health is required for the ultimate validation of these therapeutics
generallimitations sectionKeywords: gap promising preclinical results fail translate human efficacy - Review Areca Thirteen Pill (GY-13) for depression: a ConPhyMP-Informed critical review of material definition, pharmacological evidence, and translational Heyi-neuroplasticity-stress hypotheses (2026) · Frontiers in Pharmacology · doi
The lack of prospective registration, independent screening and extraction, and validated risk-of-bias assessment. The absence of a reproducible chain linking authenticated and chemically defined materials to dose, exposure, pharmacological endpoint, and clinical outcome. The heterogeneity of study designs, outcomes, and incomplete numerical reporting, which precluded quantitative pooling and meta-analysis.
generalstated challengesKeywords: lack prospective registration independent screening extraction validated risk-of-bias - Gegen Qinlian Decoction, a classic traditional Chinese medicine formula: a potential therapeutic strategy for ulcerative colitis and colorectal cancer (2026) · Frontiers in Pharmacology · doi
Future research should focus on strengthening clinical validation through standardized trial design; formula standardization and quality-marker-based establishing control; optimizing oral bioavailability and colon-targeted exposure; improving experimental reproducibility through harmonization of models, doses, and endpoints; and moving from associative mechanisms to causal validation.
generalconclusionsevidence 5/5Keywords: validation future focus strengthening clinical standardized trial design formula standardization quality marker based establishing control
Questions about this gap
Explore this gap further
Run this gap as a query across open scholarly engines for the latest related literature.
Working on this gap? Review it with us.
Science AI Journal reviews manuscripts in one pass with 8 specialised AI agents calibrated on 69,000+ real peer reviews.
Tools for your next paper
Related gaps in Medicine
- Effect across methodologically diverse studies ratherEffect across methodologically diverse studies rather than as a uni- form effect expected in all populations. The findings are summarized in…
- There are certain concerns with According to this reviewThere are certain concerns with According to this review, biomarkers are playing an increasingly important role in cancer detection, prognos…
- That should be considered when interpreting the resultsthat should be considered when interpreting the results. First, the retrospective nature of the study may introduce biases related to data c…
- Integrating plaque composition with stenosis assessmentIntegrating plaque composition with stenosis assessment for better functional and prognostic interpretation. Emerging evidence supports CT-b…